[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yunlong Wang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100643817","the-combine-af-trial-100643817",false,"NCT07633509","The COMBINE-AF Trial","A Multicenter, Prospective, Randomized Controlled Trial of Combined Pulsed-Field and Radiofrequency-Modified Linear Ablation Versus Pulsed-Field Ablation Alone for Long-Standing Persistent Atrial Fibrillation","COMBINE-AF","Inclusion Criteria:\n\n* Symptomatic patients with long-standing persistent atrial fibrillation.\n* Duration of atrial fibrillation between 1 and 3 years.\n* Age 18 to 75 years.\n* Documentation of atrial fibrillation within 3 years prior to enrollment.\n* Willing and able to comply with the study protocol and provide written informed consent.\n\nExclusion Criteria:\n\n* Paroxysmal atrial fibrillation, or evidence of sinus rhythm on electrocardiogram within the past year.\n* Persistent atrial fibrillation lasting less than 1 year or more than 3 years.\n* Left atrial thrombus.\n* Prior catheter ablation for atrial fibrillation.\n* Coexisting severe organic heart disease (e.g., severe valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.).\n* Left atrial diameter (LAD) \\>55 mm.\n* Left ventricular ejection fraction (LVEF) \\\u003C40%.\n* Known allergy or contraindication to low-molecular-weight heparin, warfarin, or direct oral anticoagulants.\n* Undergoing a \"one-stop\" procedure combining atrial fibrillation ablation with left atrial appendage closure.\n* Allergy to alcohol or contrast media.\n* Pulmonary artery systolic pressure \\>50 mmHg.\n* Unstable angina pectoris.\n* Percutaneous coronary intervention (PCI) within the past 3 months.\n* Cardiac surgery within the past 6 months.\n* Planned heart transplantation.\n* History of thromboembolic disease within the past 6 months (including venous thromboembolism: pulmonary embolism, deep vein thrombosis; or arterial thromboembolic disease: acute coronary syndrome, lower extremity arterial embolism, stroke).\n* Left atrial myxoma.\n* Severe respiratory disease.\n* Active infectious disease.\n* Poorly controlled or active systemic immune disease (equivalent to glucocorticoid use \\>2 tablets\u002Fday).\n* Unresolved malignant hematologic disease, or currently receiving chemotherapy, radiotherapy, or immunotherapy.\n* Unresolved malignant solid tumor, or currently receiving chemotherapy, radiotherapy, or immunotherapy.\n* Untreated hypothyroidism or hyperthyroidism.\n* Severe hepatic insufficiency (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] \\>3 times the upper limit of normal).\n* End-stage renal failure requiring dialysis.\n* Other serious arrhythmias, such as hemodynamically unstable ventricular tachycardia.\n* Pregnancy or breast-feeding.\n* Psychiatric disorder.\n* Body mass index (BMI) \\\u003C18.5 or \\>35.0 kg\u002Fm².\n* Life expectancy \\\u003C2 years.","ALL","18 Years","75 Years",{"count":21,"type":22},430,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to test if a more complete ablation procedure works better than the standard procedure for people with long-lasting persistent atrial fibrillation (AF). AF is a heart rhythm problem that can cause a fast or uneven heartbeat.\n\nThis study will include 430 people with long-lasting AF that has lasted 1 to 3 years. Participants will be put into one of two groups by chance:\n\nFirst group (control): They will receive pulsed-field ablation (PFA), a type of energy that can stop the faulty heart signals. They will have isolation of the pulmonary veins and the posterior wall of the left atrium.\n\nSecond group (study): They will receive the same PFA procedure plus extra ablation lines (modified linear ablation) using radiofrequency energy. This includes ablation of the mitral isthmus (with ethanol infusion into a small vein called the vein of Marshall) and the cavotricuspid isthmus.\n\nParticipants will be followed for 12 months after the procedure with clinic visits, electrocardiograms (ECGs), and heart rhythm monitors. The main outcome is whether participants stay in normal heart rhythm (sinus rhythm) without any AF episodes lasting more than 30 seconds at 12 months. Researchers will also look at procedure time, complication rates, quality of life, and other rhythm outcomes.\n\nThis study will help show if the more complete ablation procedure leads to better long-term results for people with long-lasting AF.",[28,29],"Atrial Fibrillation (AF)","Atrial Fibrillation Catheter Ablation",[31,32,33,34,35],"Atrial Fibrillation","Catheter Ablation","Long-standing Persistent Atrial Fibrillation","Pulsed Field Ablation","Radiofrequency Ablation","NOT_YET_RECRUITING","2026-07-24",{"date":39,"type":40},"2026-07-27","ACTUAL",{"date":39,"type":22},{"date":43,"type":22},"2029-12-31",{"name":45,"class":46},"Yunlong Wang","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100648063","phase-4-effect-of-tirzepatide-on-recurrence-of-atrial-fibrillation-after-catheter-ablation-in-obese-patients-100648063","NCT07715929","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients: A Multicenter, Randomized, Open-Label Trial","TEAR-AF","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years at the time of screening\n* Documented symptomatic paroxysmal AF or persistent AF, confirmed by 12-lead ECG, Holter monitoring, or cardiac monitoring device, with documented AF episode duration ≥7 days (for persistent AF) and total AF history duration ≤5 years\n* Body weight criteria (aligned with NMPA-approved tirzepatide indication) meeting at least one of the following:\n\nBMI ≥28.0 kg\u002Fm² (obesity threshold per Chinese criteria), OR BMI ≥24.0 kg\u002Fm² and \\\u003C28.0 kg\u002Fm² (overweight per Chinese criteria) with at least one weight-related comorbidity: hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM), obstructive sleep apnea syndrome (OSAS), or atherosclerotic cardiovascular disease (ASCVD)\n\n* Failed response to or intolerance of at least one antiarrhythmic drug (AAD), or explicit patient preference for a rhythm control strategy\n* Undergoing catheter ablation for AF at a participating center, with confirmed successful restoration of sinus rhythm at the end of the procedure (as determined by the operator)\n* Willing and able to understand the study procedures, provide written informed consent, and comply with all protocol requirements including 12-month follow-up visits\n* Capable of performing basic physical activity (no absolute contraindication to moderate-intensity aerobic exercise)\n\nExclusion Criteria:\n\nCardiovascular Exclusion Criteria\n\n* Long-standing persistent AF: continuous AF duration ≥5 years prior to enrollment\n* Prior catheter ablation for AF or atrial flutter at any time\n* Left atrial anteroposterior diameter \\>55 mm (by transthoracic echocardiography at screening)\n* Left ventricular ejection fraction (LVEF) \\\u003C35% at screening\n* NYHA functional class III or IV heart failure\n* Significant structural heart disease: hypertrophic cardiomyopathy, valvular heart disease requiring intervention, congenital heart disease, myocarditis, or cardiac sarcoidosis\n* Acute coronary syndrome (ACS), ischemic stroke\u002FTIA, or major cardiac surgery within 6 months prior to screening\n\nTirzepatide-Specific Exclusion Criteria (per NMPA Prescribing Information)\n\n* Prior use of any GLP-1 receptor agonist (liraglutide, semaglutide, dulaglutide, exenatide, etc.) or GIP receptor agonist, or known hypersensitivity to tirzepatide or any excipient in the formulation\n* Personal or family (first-degree relative) history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)\n* History of acute pancreatitis or chronic pancreatitis, or current symptomatic cholelithiasis or cholecystitis\n* Type 1 DM\n* Severe gastrointestinal disease including severe gastroparesis, inflammatory bowel disease, or any condition that would substantially impair gastrointestinal motility or absorption\n\nGeneral Exclusion Criteria\n\n* Use of any weight-loss medication (orlistat, phentermine, naltrexone\u002Fbupropion, or other anti-obesity agents) or participation in any weight-loss pharmacotherapy clinical trial within 3 months prior to screening\n* Severe hepatic insufficiency (Child-Pugh class C) or severe renal insufficiency (eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²)\n* Active malignancy (receiving systemic anti-cancer treatment or with life expectancy \\\u003C2 years due to malignancy)\n* Pregnancy, breastfeeding, or women of childbearing potential who are unwilling to use highly effective contraception throughout the study and for ≥1 month after the last dose of tirzepatide\n* Severe psychiatric disorder (schizophrenia, bipolar disorder, severe major depressive disorder) that would impair ability to comply with study procedures\n* Known allergy or sensitivity to adhesive patch materials (relevant to ECG monitoring patch components)\n* Any other condition that, in the opinion of the investigator, would make participation inadvisable or compromise the safety of the participant or the integrity of the study",{"count":56,"type":22},710,[58],"PHASE4","Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to sustain. Tirzepatide, a once-weekly GIP\u002FGLP-1 dual receptor agonist, produces greater weight loss than GLP-1 monotherapy and may confer additional cardiometabolic benefits. This multicenter, randomized, open-label, parallel-group, superiority trial evaluates whether adding standardized tirzepatide treatment to a structured lifestyle intervention - compared with the lifestyle intervention alone - reduces AF recurrence within 1 year after ablation in obese patients.",[31,61,32],"Obesity & Overweight",[31,63,64],"Tirzepatide","GIP\u002FGLP-1 receptor agonist","2026-07-15",{"date":67,"type":40},"2026-07-21",{"date":69,"type":22},"2026-09-01",{"date":71,"type":22},"2029-12-30",{"name":45,"class":46},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100639226","phase-4-tirzepatide-on-atrial-fibrillation-recurrence-after-catheter-ablation-in-patients-with-obesity-and-hfpef-100639226","NCT07630454","Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Obese and HFpEF: A Randomized Controlled Trial","TEAR-AF-HFpEF","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Symptomatic atrial fibrillation (paroxysmal or persistent of ≤ 5 years duration), undergoing first-time catheter ablation\n* Body weight criteria (aligned with NMPA-approved tirzepatide indication)，meeting at least one of the following:\n\n  * BMI ≥28.0 kg\u002Fm² (obesity threshold per Chinese criteria), OR\n  * BMI ≥24.0 kg\u002Fm² and \\\u003C28.0 kg\u002Fm² (overweight per Chinese criteria) with at least one weight-related comorbidity: hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM), obstructive sleep apnea syndrome (OSAS), or atherosclerotic cardiovascular disease (ASCVD)\n* HFpEF defined by intraprocedural mean left atrial pressure ≥ 15 mmHg at rest\n* Left ventricular ejection fraction ≥ 50% on echocardiography within 30 days prior to enrollment\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Prior use of any GLP-1 receptor agonist or GIP\u002FGLP-1 dual receptor agonist\n* Type 1 diabetes mellitus; or type 2 diabetes with HbA1c \\> 10%\n* Personal history of pancreatitis; personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)\n* Severe gastrointestinal disease, including gastroparesis or active inflammatory bowel disease\n* Prior bariatric surgery\n* Moderate or severe valvular heart disease, hypertrophic cardiomyopathy, cardiac amyloidosis, constrictive pericarditis, or restrictive cardiomyopathy\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Active malignancy, excluding basal cell carcinoma\n* Acute coronary syndrome, stroke, percutaneous coronary intervention, or cardiac surgery within 30 days prior to enrollment\n* Pregnancy, lactation, or planned pregnancy within 6 months\n* Life expectancy \\\u003C 12 months\n* Concurrent participation in another interventional clinical trial\n* Any condition that, in the investigator's judgment, would interfere with participation","80 Years",{"count":83,"type":22},602,[58],"This multicenter, randomized, open-label, blinded-endpoint trial evaluates whether weekly subcutaneous tirzepatide for 12 months reduces atrial fibrillation (AF) recurrence after catheter ablation in adults with obesity and heart failure with preserved ejection fraction (HFpEF). HFpEF is diagnosed by direct intraprocedural measurement of mean left atrial pressure (mLAP ≥ 15 mmHg at rest) during the ablation procedure, providing a hemodynamically anchored, homogeneous study population free from the diagnostic ambiguities of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and E\u002Fe' in AF patients. Approximately 602 participants will be randomized 1:1 to tirzepatide (titrated to a target of 10 mg\u002Fweek, maximum 15 mg\u002Fweek) plus standard care, or standard care alone. Both groups receive an identical structured lifestyle intervention. The primary endpoint is the first documented AF\u002Fatrial flutter\u002Fatrial tachycardia episode lasting ≥ 30 seconds, occurring between day 91 and day 365 after ablation, adjudicated by an independent blinded clinical endpoint committee.",[31,87,63],"Heart Failure With Preserved Ejection Fraction (HFpEF)",[31,63,64,89,90],"Obesity","HFpEF","2026-06-03",{"date":93,"type":40},"2026-06-05",{"date":95,"type":22},"2026-08-01",{"date":97,"type":22},"2029-12-01",{"name":45,"class":46},1,""]